- Conditions
- Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
- Interventions
- Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
- Other
- Lead sponsor
- University of Calgary
- Other
- Eligibility
- 9 Months to 21 Years
- Enrollment
- 1,040 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 107
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
- Interventions
- QUELIMMUNE (SCD-PED)
- Device
- Lead sponsor
- SeaStar Medical
- Industry
- Eligibility
- Up to 22 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Francisco, California + 11 more
- Conditions
- Pharmacokinetics
- Interventions
- Cefiderocol
- Drug
- Lead sponsor
- Hartford Hospital
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Acute Kidney Injury
- Interventions
- SBI-101, Sham
- Biological · Device
- Lead sponsor
- Sentien Biotechnologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Allentown, Pennsylvania
- Conditions
- Anemia
- Interventions
- ferumoxytol or oral iron
- Drug
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 19
- States / cities
- Encino, California • Riverside, California • Tarzana, California + 15 more
- Conditions
- Anemia
- Interventions
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • San Diego, California • Detroit, Michigan + 2 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Not listed
- Lead sponsor
- Arbor Research Collaborative for Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,946 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Infection During Renal Replacement Therapy, Critically Ill
- Interventions
- Ceftaroline levels in CRRT
- Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Acute Kidney Injury, Biomarkers
- Interventions
- ESTOP - AKI 2.0
- Device
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Madison, Wisconsin
- Conditions
- COVID-19
- Interventions
- CytoSorb 300 mL device
- Device
- Lead sponsor
- CytoSorbents, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Chicago, Illinois • Indianapolis, Indiana + 4 more
- Conditions
- Fabry Disease
- Interventions
- DRX005B
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- End Stage Renal Disease, Olfactory Disorders
- Interventions
- Theophylline
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Fabry Disease, Proteinuria
- Interventions
- Not listed
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 14 Years to 95 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Infections Joint Prosthetic, Overweight or Obesity, MSSA Colonization, MRSA, Chronic Kidney Diseases, Diabetes, Autoimmune Diseases, Inflammatory Disease, Tobacco Use
- Interventions
- Cephalexin, Doxycycline, Cefadroxil
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 4,618 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Rochester, Minnesota
- Conditions
- End Stage Renal Disease
- Interventions
- basiliximab
- Drug
- Lead sponsor
- Drexel University College of Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Kidney Injury, Heart Failure
- Interventions
- Not listed
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Acute Kidney Injury, End Stage Chronic Renal Failure, Dialysis
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Kidney Injury
- Interventions
- Discontinuation of CRRT
- Procedure
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Renal Failure Chronic Requiring Hemodialysis
- Interventions
- Soluble Ferric Pyrophosphate (SFP), Standard dialysate
- Drug · Device
- Lead sponsor
- Rockwell Medical Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 45
- States / cities
- Bakersfield, California • Chula Vista, California • Cudahy, California + 37 more
- Conditions
- Continuous Renal Replacement Therapy, Renal Failure, Hemofilter Clotting
- Interventions
- Calculated Post-Filter Hematocrit, Measured Post-Filter Hematocrit
- Other
- Lead sponsor
- Gwyndolyn M. Radford
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Continuous Renal Replacement Therapy
- Interventions
- use of continuous renal replacement machine for renal replacement, use of blood volume monitoring device in conjunction with machine used for continuous renal replacement to assess and determine volume removal
- Device
- Lead sponsor
- Dallas VA Medical Center
- Federal
- Eligibility
- 21 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hemophilia A
- Interventions
- Kogenate (BAY 14-2222)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 12 Years to 60 Years · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Las Vegas, Nevada
- Conditions
- Acute Kidney Injury, Liver Disease, Chronic Kidney Disease, End Stage Kidney Disease
- Interventions
- Renal replacement therapy
- Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Renal Failure, End Stage Renal Disease, Hemodialysis, Vascular Access
- Interventions
- Human Acellular Vessel (HAV), ePTFE graft
- Biological · Device
- Lead sponsor
- Humacyte, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fresno, California + 18 more